Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals (FLARE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04499677
Recruitment Status : Recruiting
First Posted : August 5, 2020
Last Update Posted : April 30, 2021
Sponsor:
Collaborator:
LifeArc
Information provided by (Responsible Party):
University College, London

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The current pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emergency. COVID-19 appears to be a disease with an early phase where the virus replicates, coinciding with first presentation of symptoms, followed by a later 'inflammatory' phase which results in severe disease in some individuals. It is known from other rapidly progressive infections such as sepsis and influenza that early treatment with antimicrobials is associated with better outcome. Antiviral medications are most likely to be effective when administered soon after infection. There is therefore an urgent need to study subjects who have recently developed symptoms, or have recently been tested positive with or without symptoms, and who can be sampled frequently to understand changes in viral load. This cohort will allow us to collect detailed trajectory data on early disease and understand how pharmacological interventions may affect this. The objective of the FLARE trial is to assess whether early antiviral therapy with either favipiravir + Lopinavir/ritonavir (LPV/r), LPV/r or favipiravir is associated with a decrease in viral load compared with placebo. The hypothesis is that this holds for COVID-19 and that early antiviral treatment may prevent progression to the later phase of the disease.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: Favipiravir Drug: Lopinavir/ Ritonavir Other: Favipiravir Placebo Other: Lopinavir/ Ritonavir Placebo Phase 2

Detailed Description:

FLARE is a phase IIA randomised, double-blind, 2x2 factorial placebo-controlled, interventional trial in which 240 participants, aged 18 years (≥ 18 years) to 70 years old inclusive will be recruited. Participants will be adults who have developed the early symptoms of COVID-19 within the first 5 days, or tested positive for SARS-CoV-2 within the first 7 days of symptom onset, or not presenting symptoms but tested positive within the last 48 hours (date/time of test must be within 48 hours of enrolment).

Eligible participants will be randomised 1:1:1:1 to receive one of the following combinations:

Favipiravir + Lopinavir/ritonavir (LPV/r) (both active); Favipiravir active + Lopinavir/ritonavir (LPV/r) placebo; Favipiravir placebo + Lopinavir/ritonavir (LPV/r) active; Favipiravir placebo + Lopinavir/ritonavir (LPV/r) placebo;

All participants will be enrolled and followed up for 28 days. A saliva sample for virological analysis and safety blood samples will be collected at baseline, as well as a diagnostic nose and throat swab, if the participant hasn't been tested for COVID-19 yet. Following randomisation, participants will take trial medication for 7 days and during this period will take a daily saliva sample and complete a symptoms diary including four daily temperature measurements.

Participants will have two follow-up visits at Day 7 and Day 14 where they will be assessed and undergo blood tests for toxicity and pharmacokinetic assessment (on Day 7 only) and provide stool samples. Participants will have a telephone follow up three (3) weeks after their last day of treatment (Day 7) and further information will be collected through a questionnaire.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Intervention Model Description: Randomised, double-blind, 2x2 factorial placebo-controlled
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Double-blind
Primary Purpose: Treatment
Official Title: Favipiravir, Lopinavir/Ritonavir or Combination Therapy: a Randomised, Double Blind, 2x2 Factorial Placebo-controlled Trial of Early Antiviral Therapy in COVID-19
Actual Study Start Date : September 24, 2020
Estimated Primary Completion Date : November 30, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Favipiravir + Lopinavir/ritonavir (LPV/r)
Oral favipiravir at 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) at 400mg/100 mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7
 Drug: Favipiravir
Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
Other Name: Avigan

Drug: Lopinavir/ Ritonavir
Dosage and method of administration: Day 1: 400mg/100 mg twice daily; Day 2 to Day 7: 200mg/50mg four (4) times daily
Other Name: Kaletra
Experimental: Favipiravir + Lopinavir/ritonavir (LPV/r) placebo
Oral favipiravir at 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
 Drug: Favipiravir
Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
Other Name: Avigan

Other: Lopinavir/ Ritonavir Placebo
Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
Experimental: Favipiravir placebo + Lopinavir/ritonavir (LPV/r)
Oral favipiravir matched placebo at 1800 mg twice daily on Day 1, by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
 Drug: Lopinavir/ Ritonavir
Dosage and method of administration: Day 1: 400mg/100 mg twice daily; Day 2 to Day 7: 200mg/50mg four (4) times daily
Other Name: Kaletra

Other: Favipiravir Placebo
Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
Placebo Comparator: Favipiravir placebo + Lopinavir/ritonavir (LPV/r) placebo
Oral favipiravir matched placebo at 1800 mg twice daily on Day 1, by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
 Other: Favipiravir Placebo
Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.

Other: Lopinavir/ Ritonavir Placebo
Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Upper respiratory tract viral load at Day 5 [ Time Frame: Day 5 from randomisation ]
    Quantitative polymerase chain reaction (PCR) performed on saliva samples at Day 5 of therapy


Secondary Outcome Measures :
  1. Percentage of participants with undetectable upper respiratory tract viral load after 5 days of therapy [ Time Frame: 5 days from randomisation ]
    Quantitative polymerase chain reaction (PCR) performed on saliva samples at Day 5 of therapy

  2. Proportion of participants with undetectable stool viral load after 7 days of therapy. [ Time Frame: 7 days from randomisation ]
    Quantitative polymerase chain reaction (PCR) performed on stool samples at Day 7

  3. Rate of decrease in upper respiratory tract viral load during 7 days of therapy [ Time Frame: 7 days ]
    PCR performed on daily saliva samples collected between Day 1 and Day 7 post-randomisation

  4. Duration of fever following commencement of medication [ Time Frame: 7 days ]
    Daily body temperature records between Day 1 and Day 7 post-randomisation

  5. Proportion of participants with hepatotoxicity after 7 days of therapy [ Time Frame: 7 days from randomisation ]
    Standard diagnostic laboratory assays for liver transaminases, alkaline phosphatase and bilirubin

  6. Proportion of participants with other medication-related toxicity after 7 days of therapy and 14 days post-randomisation [ Time Frame: Day 7 and Day 14 from randomisation ]
    Determination of medication-related adverse events by investigators at Day 7 and Day 14 post-randomisation

  7. Proportion of participants admitted to hospital with COVID-19 related illness [ Time Frame: 28 days ]
    Participant self-report, review of hospital records and discharge summaries within 28 days of randomisation

  8. Proportion of participants admitted to ICU with COVID-19 related illness [ Time Frame: 28 days ]
    Participant self-report, review of hospital records and discharge summaries within 28 days of randomisation

  9. Proportion of participants who have died with COVID-19 related illness [ Time Frame: 28 days ]
    Participant self-report, review of hospital records and discharge summaries within 28 days of randomisation

  10. Pharmacokinetics of favipiravir as measured by Clearance (CL) [ Time Frame: Day 7 from randomisation ]
    Assess pharmacokinetics of favipiravir as measured by Clearance (CL)

  11. Pharmacokinetics of favipiravir as measured by Volume of distribution (V) [ Time Frame: Day 7 from randomisation ]
    Assess pharmacokinetics of favipiravir as measured by Volume of distribution (V)

  12. Pharmacokinetics of favipiravir as measured by Absorption rate constant (Ka) [ Time Frame: Day 7 from randomisation ]
    Assess pharmacokinetics of favipiravir as measured by Absorption rate constant (Ka)

  13. Pharmacokinetics of favipiravir as measured by Maximum concentration (Cmax) [ Time Frame: Day 7 from randomisation ]
    Assess pharmacokinetics of favipiravir as measured by Maximum concentration (Cmax)

  14. Pharmacokinetics of favipiravir as measured by Time to maximum concentration (Tmax) [ Time Frame: Day 7 from randomisation ]
    Assess pharmacokinetics of favipiravir as measured by Time to maximum concentration (Tmax)

  15. Pharmacokinetics of favipiravir as measured by Elimination rate constant (Ke) [ Time Frame: Day 7 from randomisation ]
    Assess pharmacokinetics of favipiravir as measured by Elimination rate constant (Ke)

  16. Pharmacokinetics of favipiravir as measured by Area Under the Curve extrapolated to infinity (AUC (0-inf) [ Time Frame: Day 7 from randomisation ]
    Assess pharmacokinetics of favipiravir as measured by Area Under the Curve extrapolated to infinity (AUC (0-inf)

  17. Pharmacodynamics of favipiravir as measured by Rate of viral load decline (delta) [ Time Frame: Day 7 from randomisation ]
    Assess pharmacodynamics of favipiravir as measured by Rate of viral load decline (delta)

  18. Pharmacodynamics of favipiravir as measured by Maximum increase in viral load under drug treatment (Emax) [ Time Frame: Day 7 from randomisation ]
    Assess pharmacodynamics of favipiravir as measured by Maximum increase in viral load under drug treatment (Emax)

  19. Pharmacodynamics of favipiravir as measured by Concentration to achieve half the maximum possible effect (EC50) [ Time Frame: Day 7 from randomisation ]
    Assess pharmacodynamics of favipiravir as measured by Concentration to achieve half the maximum possible effect (EC50)

  20. Proportion of participants with deleterious or resistance-conferring mutations in SARS-CoV-2 by Day 7 of treatment [ Time Frame: Day 7 from randomisation ]
    Deep sequencing of virus and bioinformatic analysis


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Any adult with the following:

    • Symptoms compatible with COVID-19 disease (Fever >37.8oC on at least one occasion AND either cough and/ or anosmia) within the first 5 days of symptom onset
    • OR ANY symptoms compatible with COVID-19 disease (may include, but are not limited to fever, cough, shortness of breath, malaise, myalgia, headache, coryza) and tested positive for SARS-CoV-2 within the first 7 days of symptom onset
    • OR no symptoms but tested positive for SARS-CoV-2 within the last 48 hours (date/time of test must be within 48 hours of enrolment)
  2. Male or female aged 18 years to 70 years old inclusive at screening
  3. Willing and able to take daily saliva samples
  4. Able to provide full informed consent and willing to comply with trial-related procedures

Exclusion Criteria:

  1. Known hypersensitivity to any of the active ingredients or excipients in favipiravir and matched placebo, and in lopinavir/ritonavir and matched placebo
  2. Chronic liver disease at screening (known cirrhosis of any aetiology, chronic hepatitis (e.g. autoimmune, viral, steatohepatitis), cholangitis or any known elevation of liver aminotransferases with AST or ALT > 3 X ULN)*
  3. Chronic kidney disease (stage 3 or beyond) at screening: eGFR < 60 ml/min/1.73m2*
  4. HIV infection, if untreated, detectable viral load or on protease inhibitor therapy
  5. Any clinical condition which the investigator considers would make the participant unsuitable for the trial
  6. Concomitant medications known to interact with favipiravir and matched placebo, and with lopinavir/ritonavir and matched placebo, and carry risk of toxicity for the participant
  7. Current severe illness requiring hospitalisation
  8. Pregnancy and/ or breastfeeding
  9. Eligible female participants of childbearing potential and male participants with a partner of childbearing potential not willing to use highly effective contraceptive measures during the trial and within the time point specified following last trial treatment dose.
  10. Participants enrolled in any other interventional drug or vaccine trial (co-enrolment in observational studies is acceptable).

  11. Participants who have received the COVID-19 vaccine

    • Considering the importance of early treatment of COVID-19 to impact viral load, the absence of chronic liver/ kidney disease will be confirmed verbally by the participant during pre-screening and Screening/Baseline visit. Safety blood samples will be collected at Screening/Baseline visit (Day 1) and test results will be examined as soon as they become available within 24 hours.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04499677


Contacts
Layout table for location contacts
Contact: FLARE Trial Team UCL CCTU 020 3108 9840 cctu.flare@ucl.ac.uk

Locations
Layout table for location information
United Kingdom
Royal Free Hospital Recruiting
London, United Kingdom, NW3 2QG
Contact: David Lowe    02078302141    d.lowe@ucl.ac.uk   
Contact       d.lowe@ucl.ac.uk   
Principal Investigator: David Lowe         
University College London Hospital (UCLH) Recruiting
London, United Kingdom
Contact: Nicky Longley    07341 776 401    uclh.infectionresearchHTD@nhs.net   
Contact: Anna Checkley    07341 776 401    uclh.infectionresearchHTD@nhs.net   
Principal Investigator: Nicky Longley         
Sub-Investigator: Anna Checkley         
Sponsors and Collaborators
University College, London
LifeArc
Investigators
Layout table for investigator information
Principal Investigator: David Lowe Institute of Immunity and Transplantation, University College London
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: University College, London
ClinicalTrials.gov Identifier: NCT04499677    
Other Study ID Numbers: 132084
First Posted: August 5, 2020    Key Record Dates
Last Update Posted: April 30, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: No plan to share IPD has been made at this time.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Antiviral Agents
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
 Ritonavir
Lopinavir
Favipiravir
HIV Protease Inhibitors
Viral Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors